PharMerica serves bidder a poison pill

Share this article:

Just days after rejecting a $456 million purchase offer, the board at PharMerica Corp. adopted a poison-pill defense. The measure is intended to prevent Omnicare Inc. from obtaining control of PharMerica “in a manner or on terms that are not in the best interests of the company," according to the firm. The maneuver trades rights with PharMerica common stock. These rights would be exercisable should a person or group amass 15% or more of the company's common stock without board approval or announces a tender offer that attempts to do so. The companies are the two largest providers of pharmaceutical services in the long-term care sector.

Share this article:

More in Products

FDA approves weight management drug

The U.S. Food and Drug Administration has approved Contrave as a treatment for chronic weight management. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation.

PDI introduces new swab

PDI introduces new swab

PDI has debuted the Prevantics® Device Swab, a chlorhexidine gluconate/alcohol solution that has received market authorization from the U.S. Food and Drug Administration for disinfecting needleless access sites prior to ...

Oregon Freeze Dry releases Easy Meal

Oregon Freeze Dry releases Easy Meal

A new brand from Oregon Freeze Dry is designed to help long-term care and other healthcare facilities prepare for a disaster.